Neuronetics (STIM) announced that it has settled the litigation filed in the District of Delaware against BrainsWay (BWAY) and BrainsWay USA Inc. for unfair competition under the Lanham Act and state law. Under the terms of the settlement, BrainsWay agreed to stop the use of the efficacy data for the treatment of anxious depression with NeuroStar Advanced Therapy for Mental Health that was at issue in the Complaint filed by Neuronetics. The parties have agreed to keep the additional terms of the settlement agreement confidential.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on STIM:
- Neuronetics Settles Litigation Against BrainsWay
- Neuronetics momentum likely to prove durable, says Piper Sandler
- Neuronetics sees Q4 revenue $18M, consensus $16.54M
- Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results
- Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors